Intravitreal Ranibizumab in a Patient with Choroidal Neovascularization Secondary to Multiple Evanescent White Dot Syndrome

Abstract

Intravitreal ranibizumab appears to be a safe and effective treatment option in cases of CNV secondary to MEWDS, resulting in fast resolution of the macular edema and regression of the CNV. On the other hand, it is unclear whether the administration of ranibizumab contributed to a prompt regression of MEWDS.